OncoMatch/Clinical Trials/NCT05941156
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
Is NCT05941156 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anti-CD56 CAR T for extranodal nk t cell lymphoma.
Treatment: Anti-CD56 CAR T — To evaluate the safety and efficacy of anti-CD56-CAR T in the treatment of relapsed refractory NK/T cell lymphoma /NK cell leukemia
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
relapse after chemotherapy
Must have received: hematopoietic stem cell transplantation
relapse after hematopoietic stem cell transplantation
Must have received: cellular immunotherapy
relapse or no remission after hematopoietic stem cell transplantation or cellular immunotherapy
Lab requirements
Kidney function
creatinine < 220 μmol/l
Liver function
alt/ast < 3 times the upper limit of normal (uln) and total bilirubin ≤34.2μmol/l
Cardiac function
left ventricular ejection fraction (lvef) ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify